Catalyst gains FDA approval for reverse shoulder system

Catalyst OrthoScience received 510(k) clearance from the FDA to market its reverse shoulder system and expects to commercially launch the shoulder system later this year. 

Advertisement

The reverse shoulder system is designed for patients experiencing severe shoulder arthritis coinciding with a deficient rotator cuff, according to a March 17 press release by the company. 

Reverse shoulder arthroplasty is estimated to encompass more than 60 percent of the shoulder market. The reverse shoulder system’s single-tray arthroplasty system will streamline procedures, making them easier and more efficient. 

The commercial launch of the reverse shoulder system will expand the company’s arthroplasty options, which include its CSR Total Shoulder System. 

More articles on spine:
What 2 spine surgeons think about CMS’s plans to eliminate the inpatient only list
Spine surgery in 2030 — 6 surgeon predictions
Neurosurgeon’s license restricted over unnecessary spine surgery allegations: 4 details

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.